Tag Archives: England

UK: Patient Group Sets Out Orphan Drug Charter

By Leela Barham. There has been a lot of concern about the decision to give the National Institute for Health and Care Excellence (NICE) the responsibility to look at “highly specialized technologies” (HSTs, or orphan drugs to you and me). That decision was taken just as the NHS across England was going through major reform […]
Posted in Europe, Global, Guest Blog, healthcare, Op-Ed, Orphan Drugs, Patient Communication, patient education, pricing, Regulatory | Also tagged , , , , , , , | Leave a comment

England: Ignoring NICE Guidelines Can Be Unlawful

By Leela Barham. An administrative court has said that a Clinical Commission Group (CCG, a local budget holder for the National Health Service in England) can’t just disagree with guidance from the UK’s National Institute for Health and Clinical Excellence (NICE) — that’s unlawful.
Posted in Europe, Guest Blog, pricing, Regulatory | Also tagged , , , , | Leave a comment

Pursuing the 'Real' Cost Effectiveness Threshold in England

By Leela Barham. The Incremental Cost Effectiveness Ratio (ICER) thresholds used by agencies such as the UK’s National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and as far afield as Australia by the Pharmaceutical Benefits Advisory Committee (PBAC) are often controversial. This is mostly because it means analysts saying that a […]
Posted in Europe, Guest Blog, Op-Ed, pricing | Also tagged , , , , , , , , , | Leave a comment

England's Latest Innovation Scorecard: A Patchy Picture

By Leela Barham. A common gripe from those in the pharma industry in England is that even when their products have been found to be cost effective by the National Institute for Health and Care Excellence (NICE) (not always easy to do these days), uptake in the NHS can be ‘low and slow’.  The latest […]
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , , , , | Leave a comment

The UK's New "Revolutionary" Medicines Optimization Plan

By Leela Barham. The UK’s Royal Pharmaceutical Society has joined forces with a number of other organizations, including the Association of the British Pharmaceutical Industry (ABPI), to issue new guidance on medicines optimization.  Sir Bruce Keogh, Medical Director of NHS England, says it could be revolutionary.
Posted in Europe, Global, Guest Blog, Op-Ed | Also tagged , , , , , | Leave a comment
  • Categories

  • Meta